| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/01/2006 | CN1727327A Derivative in hydroxy anthraquinones category and application |
| 02/01/2006 | CN1727319A Device in category of substitution tricyclo-diterpene-orthodiphenol, preparation method and application |
| 02/01/2006 | CN1727003A Carcinogen detoxification composition and method |
| 02/01/2006 | CN1726997A anticancer medication, and preparation method |
| 02/01/2006 | CN1726962A Method for controlling quality of cudrania wood and preparation |
| 02/01/2006 | CN1726954A Oral taking preparation of Chinese traditional medicine for treating liver cancer, and preparation method |
| 02/01/2006 | CN1726948A Medication for treating ascites of liver, cirrhosis of liver and liver cancer in early stage |
| 02/01/2006 | CN1726944A Extract product rich in gen-seng saponin in monosaccharide, preparation method and application |
| 02/01/2006 | CN1726930A Combination of effective parts for anti tumors, preparation and application |
| 02/01/2006 | CN1726928A Combination of medication for treating hysteromycoma and preparation method |
| 02/01/2006 | CN1726927A Active function of ostrich blood |
| 02/01/2006 | CN1239701C Humanised antibodies to epidermal growth factor receptor |
| 02/01/2006 | CN1239516C Tumor necrosis factor relative cell death inducing ligand extracellular region mutation polypeptide and its prepn and use |
| 02/01/2006 | CN1239492C Medication containing 1,6-methylene-[10]-annulene-furan and steroid |
| 02/01/2006 | CN1239204C Conjugates useful in treatment of prostate cancer |
| 02/01/2006 | CN1239170C Chinese patent drug for treating liver cancer |
| 02/01/2006 | CN1239167C Medicines for treating thyroma and hydatoncus |
| 02/01/2006 | CN1239160C Hormone replacement therapy |
| 01/31/2006 | USRE38962 Diphenyl-triazole derivatives and their use as anti-gestative immuno-suppressant and anti-tumoral agents |
| 01/31/2006 | US6992215 Thiol-based NAALADase inhibitors |
| 01/31/2006 | US6992207 Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| 01/31/2006 | US6992183 Reacting a polysaccharide from fermentation with isopropanol in a highly saline aqueous solution, n-deacetylation followed by n-sulfation, and treating ammonium salt with an o-sulfating agent |
| 01/31/2006 | US6992169 Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. |
| 01/31/2006 | US6992106 Anti-tumor composition |
| 01/31/2006 | US6992104 C7 carbonate taxane compositions |
| 01/31/2006 | US6992094 selenium nicotinic acid tetrahyronaphthaline compounds; treating skin disorders |
| 01/31/2006 | US6992089 Anticancer agents; bactericides, fungicides |
| 01/31/2006 | US6992088 Tetracyclic or pentacyclic cytotoxic agents, enzyme inhibitors, anticarcinogenic agents, bactericides, fungicides |
| 01/31/2006 | US6992084 Compounds and methods for modulating CXCR3 function |
| 01/31/2006 | US6992082 for treatment of cellular proliferative diseases such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation |
| 01/31/2006 | US6992080 For therapy of cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases |
| 01/31/2006 | US6992074 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/31/2006 | US6992070 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | US6991817 Acid-modified arabinogalactan protein composition |
| 01/31/2006 | US6991785 Administering by tissue absorption |
| 01/31/2006 | US6991776 Halogenated xanthene or halogenated xanthene derivative; cancer treatment |
| 01/31/2006 | CA2390104C Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins |
| 01/31/2006 | CA2327498C Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 01/31/2006 | CA2314154C Azepine or larger medium ring derivatives and their use as pharmaceuticals |
| 01/31/2006 | CA2259345C Anthranilic acid diamides derivatives, their preparation and pharmaceutical use as anti-gastrin agents |
| 01/31/2006 | CA2158855C Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents |
| 01/31/2006 | CA2119261C Novel sidechain-bearing taxanes and intermediates thereof |
| 01/31/2006 | CA2067365C Illudin analogs as anti-tumor agents |
| 01/26/2006 | WO2006009919A2 Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
| 01/26/2006 | WO2006009869A1 Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 01/26/2006 | WO2006009805A2 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| 01/26/2006 | WO2006009464A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009309A1 Galectin 9-binding protein factor |
| 01/26/2006 | WO2006009119A1 Process for production of polysubstituted cyclobutanes and polysubstituted cyclobutenes |
| 01/26/2006 | WO2006009092A1 Method of effectively using medicine and method concerning prevention of side effect |
| 01/26/2006 | WO2006008649A1 Anti-sense polynucleotide therapy for gastrin-promoted tumors |
| 01/26/2006 | WO2005120573A3 Cationic bacteriochlorophyll derivatives and uses thereof |
| 01/26/2006 | WO2005077922A3 Process for the preparation of substituted triazole compounds |
| 01/26/2006 | WO2005073236A3 Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors |
| 01/26/2006 | WO2004045532A3 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 01/26/2006 | WO2004014319A3 Screening strategy for anticancer drugs |
| 01/26/2006 | US20060020138 E.g., 3-arylmethyl-7-hydroxy-coumarins as intermediates; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/26/2006 | US20060020131 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents |
| 01/26/2006 | US20060020046 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| 01/26/2006 | US20060020024 TNP-470 species, polymer conjugates and use thereof |
| 01/26/2006 | US20060020020 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 01/26/2006 | US20060020008 Compounds, compositions and methods |
| 01/26/2006 | US20060020002 (3a alpha ,4 alpha ,7 alpha ,7a alpha )-Octahydro-3-hydroxy-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (2); steroid mimic; competitive inhibitors of intercellular ligand binding reactions involving CAMs and Leukointegrins; anticarcinogenic agent; autoimmune diseases |
| 01/26/2006 | US20060019999 Specific inhibitors of one or more isoforms of nitric oxide synthase; 3-[[2-amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile; antiinflammatory agent; pain |
| 01/26/2006 | US20060019996 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 01/26/2006 | US20060019988 Compounds, compositions, and methods |
| 01/26/2006 | US20060019977 Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient |
| 01/26/2006 | US20060019960 Antitumoral analogs of ET-743 |
| 01/26/2006 | US20060019959 Novel quinoxalinone derivatives |
| 01/26/2006 | US20060019945 Granzyme b inhibitors |
| 01/26/2006 | US20060019930 Treatment and prevention of tissue damage |
| 01/26/2006 | US20060019897 Anti-angiogenic polypeptides |
| 01/26/2006 | US20060019887 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 01/26/2006 | US20060019885 Modified bryodin 1 with reduced immunogenicity |
| 01/26/2006 | US20060019883 Use of cyclin D1 inhibitors |
| 01/26/2006 | US20060019876 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 01/26/2006 | US20060019365 IKK-alpha proteins, nucleic acids and methods |
| 01/26/2006 | US20060019344 C-erbB-2 external domain: gp75 |
| 01/26/2006 | US20060019336 Factor VII or VIIa - like molecules |
| 01/26/2006 | US20060019294 Tyrosine kinase substrate (Tks) proteins |
| 01/26/2006 | US20060019246 Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases |
| 01/26/2006 | US20060018956 Dermal application system for aminolevulinic acid-derivatives |
| 01/26/2006 | US20060018915 Heteroclitic analogs and related methods |
| 01/26/2006 | US20060018903 Tumor necrosis factors (TNF); site-directed mutagenesis, genetic deletions; monoclonal antibodies with decreased immunogenicity and lymphocyte epitopes; major histocompatibility complex binding ligands; for treatment of rheumatoid arthritis and Crohn's disease |
| 01/26/2006 | US20060018895 Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| 01/26/2006 | US20060018893 Method for determining modulation of P110delta activity |
| 01/26/2006 | US20060018892 nucleic acid molecule comprising nucleotide sequences, that code fro single chain proteins which are serine protease inhibitors, used for prophylaxis of emphysema, cirrhosis, hepatitis, blood disorders, tumors and tumor metastasis |
| 01/26/2006 | US20060018881 Coordinate in vivo gene expression |
| 01/26/2006 | DE102004032711A1 Substituierte Hydroxyacetophenonderivate Substituted hydroxyacetophenone |
| 01/26/2006 | DE102004032674A1 Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 New 2-substituted estra-1,3,5 (10) triene-17-one 17β-hydroxysteroid dehydrogenase inhibitors of type 1 |
| 01/26/2006 | DE102004032673A1 Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 New 2-substituted D-homo-estra-1,3,5 (10) -trienes 17beta-hydroxysteroid dehydrogenase inhibitors of type 1 |
| 01/26/2006 | DE102004030227A1 Treatment of diseases (e.g. proliferative diseases of tumor cells, ophthalmic diseases and skin diseases) associated with angiogenesis comprises administration of carbamide compounds |
| 01/26/2006 | CA2581068A1 Treatment of tumours |
| 01/26/2006 | CA2574204A1 Fused pyrimidones useful in the treatment and the prevention of cancer |
| 01/26/2006 | CA2573674A1 Muscarinic antagonists with parp and sir modulating activity as agents for inflammatory diseases |
| 01/26/2006 | CA2572793A1 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
| 01/26/2006 | CA2572047A1 Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof |
| 01/26/2006 | CA2570998A1 Improved efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| 01/26/2006 | CA2570968A1 Gonadotropin releasing hormone receptor antagonists |